Aa
Will failed treatment breed a more resistant virus?
Will failed treatment breed a more resistant virus to future treatments? For example, if a person were to fail to attain SVR with Ribavirin and peginterferon, would that breed a virus that is more resistant to future combination therapies such as protease or polymerase inhibitors given along with Ribavirin and peg-interferon?
It`s basically what Trinity said.This was one of my key questions before starting tx
and my reputable hepatologist told me there is no known additional resistance
created by SOC.
and my reputable hepatologist told me there is no known additional resistance
created by SOC.
Good question
Many folks that swear by herbal supplements think yes after the virus has gained resistance to a drug it becomes stronger…I would hope not do due to the fact I was a nonresponder to treatment with peg-riv.
Gordo
Sunshines76 ,thanks for the link.
Many folks that swear by herbal supplements think yes after the virus has gained resistance to a drug it becomes stronger…I would hope not do due to the fact I was a nonresponder to treatment with peg-riv.
Gordo
Sunshines76 ,thanks for the link.
Some think resistance to peg and riba occurs with failed treatment. I don't or there would not be any SVR's for those who treat multiple times and peg and riba would be ineffective in the drug trials for non responders. Resistance to the PI after failed treatment is a different story. They don't know a whole lot yet, but they do know it happens.
Trinity
Trinity
And another piece of info you might find interesting: https://www.niddkrepository.org/niddkdocs/HALT/MOOP/MOO_K16_HCVBreakthroughAS_12-27-07.pdf
From http://www.natap.org/2009/HCV/010809_01.htm
"Emergence of drug resistance in HCV must be considered to be a major threat. Furthermore, many of the resistance mutations to PIs and nucleoside analogues may produce cross-resistance to other compounds within the same drug family, which may complicate rescue-treatment options. The length of persistence of HCV resistance mutations after discontinuation of treatment must be investigated."
and
"Because it is possible to eradicate HCV from the host, it was initially thought that with regard to treatment, "the first will be the winner," which meant that the first HCV drug to gain approval would decrease the chances of success for any other drugs that arrived later. However, as more evidence demonstrates the challenge of drug resistance and the need for drug combinations, it is clear that there will be a place for many treatment compounds. In fact, multiple drugs from distinct drug families will be needed, especially if therapy without pegylated IFN is desired. These drug combinations would ideally be constructed with compounds that exhibit complementary features, such as compounds that have distinct drug resistance profiles targeting either the same enzyme (convergent therapy) or different enzymes (divergent therapy). "
"Emergence of drug resistance in HCV must be considered to be a major threat. Furthermore, many of the resistance mutations to PIs and nucleoside analogues may produce cross-resistance to other compounds within the same drug family, which may complicate rescue-treatment options. The length of persistence of HCV resistance mutations after discontinuation of treatment must be investigated."
and
"Because it is possible to eradicate HCV from the host, it was initially thought that with regard to treatment, "the first will be the winner," which meant that the first HCV drug to gain approval would decrease the chances of success for any other drugs that arrived later. However, as more evidence demonstrates the challenge of drug resistance and the need for drug combinations, it is clear that there will be a place for many treatment compounds. In fact, multiple drugs from distinct drug families will be needed, especially if therapy without pegylated IFN is desired. These drug combinations would ideally be constructed with compounds that exhibit complementary features, such as compounds that have distinct drug resistance profiles targeting either the same enzyme (convergent therapy) or different enzymes (divergent therapy). "
There is no a definite answer, but check this article out:
http://www.heart-intl.net/HEART/Hepatitis/Comp/HCV-resistanttheropy.pdf
http://www.heart-intl.net/HEART/Hepatitis/Comp/HCV-resistanttheropy.pdf
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
